RxDoctor Payments Data

James Cui, MD

Dermatology · Flushing, NYNPI 1487659512

Payments from drug & device makers

$2,279in general payments, 2019–2025

Across 83 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$830
  • Revance Therapeutics, Inc.$324
  • Johnson & Johnson$300
  • Merz North America, Inc.$208
  • AbbVie$131
  • Foundation Medicine, Inc.$117
  • plus $369 from 10 others

What the payments were for

  • Food & beverage$1,96586%
  • Education$31414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,279 in reported general payments places this provider in the 45th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$227,842
Medicare patients
605
Services billed
2,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab56$504,954
Clobetasol Propionate5,206$352,697
Skyrizi PenRisankizumab-Rzaa14$294,103
Humira(Cf) PenAdalimumab37$250,730
Dupixent PenDupilumab50$191,634
OpzeluraRuxolitinib Phosphate32$90,413
Fluocinonide1,249$87,002
Halobetasol Propionate629$61,867
Tacrolimus191$53,198
Mometasone Furoate2,472$50,344
Triamcinolone Acetonide2,183$39,281
Ketoconazole2,063$35,026
Diflorasone Diacetate53$30,421
Clotrimazole1,573$23,271
Ammonium Lactate900$23,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$25$90,41332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,151 dermatology providers in New York.

Other dermatology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →